Pharmacogenetics Unit, UGC Provincial de Farmacia de Granada, Instituto de Investigación Biosanitaria de Granada, Complejo Hospitalario Universitario de Granada, Avda. Fuerzas Armadas, 2 Spain; Department of Biochemistry, Faculty of Pharmacy, University of Granada, Campus Universitario de Cartuja, s/n 18071 Granada, Spain.
Nephrology Research Group, Centre for Public Health, Queen's University of Belfast, c/o Regional Genetics Centre, Level A, Tower Block, Belfast City Hospital, Lisburn Road, Belfast, BT9 7AB, United Kingdom.
Pathol Res Pract. 2018 Jan;214(1):44-52. doi: 10.1016/j.prp.2017.11.015. Epub 2017 Nov 21.
Lung cancer, particularly non-small cell lung cancer (NSCLC) subtype, is the leading cause of cancer-related death related worldwide. Numerous gene polymorphisms in DNA repair, folate and glutathione pathways have been associated with susceptibility of NSCLC. We conducted this study to evaluate the effects of ERCC1, ERCC2, ERCC5, XRCC1, XRCC3, MTHFR, MTR, MTHFD1, SLC19A1 and GSTP1 gene polymorphisms on risk of NSCLC. No association between these gene polymorphisms and susceptibility of NSCLC were found in our patients, suggesting that genetic variations in genes involved in DNA repair, folate and glutathione metabolism pathways may not influence the risk of NSCLC.
肺癌，尤其是非小细胞肺癌（NSCLC）亚型，是全球癌症相关死亡的主要原因。许多 DNA 修复、叶酸和谷胱甘肽途径中的基因多态性与 NSCLC 的易感性相关。我们进行了这项研究，以评估 ERCC1、ERCC2、ERCC5、XRCC1、XRCC3、MTHFR、MTR、MTHFD1、SLC19A1 和 GSTP1 基因多态性对 NSCLC 风险的影响。我们的患者中没有发现这些基因多态性与 NSCLC 易感性之间的关联，这表明参与 DNA 修复、叶酸和谷胱甘肽代谢途径的基因中的遗传变异可能不会影响 NSCLC 的风险。
